FedBizOpps banner

Login to begin searching the FBO/CBD
Home Page
CBD/FBO Online
CBD/FBO Email
About Us
Contact Us
Privacy
Categories
No. Notes
Archives
Search
Help
Login
Register

Popular Searches

Popular Categories

U.S. Ambulatory Outpatient Trial of Humira� (Adalimumab) in COVID-19

General Information

Document Type:SRCSGT
Posted Date:Aug 26, 2020
Category: Research and Development
Set Aside:N/A

Contracting Office Address

W6QK ACC-APG NATICK NATICK MA 01760-5011 USA

Description

REQUEST FOR INFORMATION U.S. Ambulatory Outpatient Trial of Humira� (Adalimumab) in COVID-19�� ****Full Announcement Attached to this Posting**** Objective: This is a Request for Information (RFI) for planning purposes only. It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited.� No solicitation document exists or is guaranteed to be issued as a result of this RFI.� The Joint Program Executive Office for Chemical and Biological Defense (Medical Countermeasures Systems) is seeking information on the capabilities and willingness of private entities (academic, non-profit and commercial) in the areas listed below. �

Original Point of Contact

POC Richard Totten, Phone: 3016192446

Place of Performance

Link: SAM.gov Permalink
Bookmark This Notice
Print View